Patient Registry for Berinert®, a C1-Esterase Inhibitor
Patient Registry for Berinert®, a C1-Esterase Inhibitor
The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.
Inclusion Criteria:
Exclusion Criteria:
Branchburg, New Jersey 08876, United States